THE OPERATOR
Science-driven, strategy-led.
I help life sciences leaders decide where to invest, what to prioritize, and how to convert scientific innovation into commercial growth and transaction value.
My experience spans ideation, discovery, and commercialization, including global innovation P&L leadership at Sartorius and MilliporeSigma across research tools and large-molecule applications.
I bring disciplined execution to critical initiatives, strategic turnarounds, and deal work. The objective is simple: make better decisions sooner, align the organization behind them, and convert strategy into measurable financial results.
Perfect information does not exist. Infallible decisions do not either.
I help clients make better decisions, then build the conviction to act on them.
$600M+
Revenue impact
100+
Financials models built
10+
M&A integrations
30%
Serviceable market expansion
An idealist who pushes for the breakthrough and the realist who strips the academic romance out of commercialization.
THESIS: DECISION SCIENCE FOR LIFE SCIENCES
1.8M+
biomedical papers in 2025, and rising
487
of global biopharma VC deals, from 780 in 2021
63.5%
of US VC dollars flowing to AI in 2025
Capital crunch in innovation.
Scientific breakthroughs are accelerating, yet the capital required seem scarce. AI absorbed 63.5% of US venture dollars in 2025 and 88.8% in Q1 2026, while the capital reaching biopharma concentrates in later-stage assets and larger rounds. Global deal count remains well below the 780 recorded in 2021, and biopharma IPOs fell from 99 in 2021 to nine in 2025. 6 listings in Q1 2026 do not restore the capital recycling needed to seed the next cohort.
Fewer therapeutics companies forming today create a thinner future customer pipeline for tools and bioprocessing long before the revenue line shows the loss. With fewer shots on goal, a single misstep cascades through the organizational network, costing millions in lot rejections, margin-thinning scale-up inefficiencies, underutilized capacity, and market-share erosion. The margin for error has vanished.
Paralysis trap.
Consensus-driven paralysis is expensive. It keeps weak programs funded two quarters too long and cedes first mover advantage to competitors. Forward-thinking organizations incorporate a venture capital mindset, funding assets with the highest risk-adjusted return potential. Leaders who know which programs to accelerate, when to cut losses, and how to act on early signals have an early advantage.
Clarity enabled velocity.
When budgets contract, speed alone is insufficient. Realizing value requires multi-lens clarity to triangulate market variables, isolate signal from noise, and execute high-stakes decisions before the market shifts. Market data tells you what is happening. Operating experience tells you what it costs to respond. Organizational reality tells you whether the response will hold. One-lens decisions are fast but risky. Decisions that sequentially wait for all three are dilutive and late.
Decision Science for Life Sciences provides the discipline to uncover hidden liabilities, de-risk operational execution, and map market white spaces before resources are committed.
By Helen Kim, Founder, Altaclara
Updated August 2026
Disciplined trade-offs increase the odds of a winning bet.
Sources: PubMed, National Library of Medicine, J.P. Morgan, Q1 2026 Biopharma Licensing and Venture Report; PitchBook-NVCA Venture Monitor, Q1 2026. Full-year 2025 figures, retrieved August 2026.
THE DECISION MODEL: AN ENDURING COMPETITIVE ADVANTAGE
Companies rarely lack data or domain expertise. They lack a mechanism to reconcile market evidence, execution reality, and organizational behavior before a decision hardens. The cost of that gap is steep: in a survey of more than 1,200 business leaders, 61% considered at least half their decision-making time ineffective.
The Decision Model triangulates three forces simultaneously. Market insight establishes commercial potential. Operator experience tests execution reality. Organizational behavior determines whether the decision will hold once incentives, stakeholders, and competing priorities enter the room.
This is not an academic model. It is built on real operating experience across strategy, R&D, marketing, manufacturing, and operations, where a single decision creates trade-offs long before it becomes a costly handoff.
When the three lenses align, teams move from fragmented expertise to decisive momentum. The result is faster resource allocation, stronger execution, and choices that survive contact with the organization.
Multi-lens triangulation improves decision quality.
Survey Source: McKinsey & Company, "Decision making in the age of urgency". April 30, 2019.
THE NETWORK REALITY: DECISIONS REVERBERATE
No critical life sciences decision stays within one function.
A portfolio choice travels from R&D through product management, operations, quality, regulatory, commercial teams, and ultimately the customer. Each handoff can either compound value or introduce friction.
An end-to-end view connects upstream scientific and technical choices to downstream financial consequences. It reveals hidden dependencies, false positives, operational bottlenecks, and points where a decision can fail long before the revenue line reflects it.
Functional fluency is the ability to reconcile incentives, synchronize actions, and move from complexity to execution. The objective is not a more detailed map. It is a network aligned behind the decisions that matter.
An aligned network converts decisions into enterprise value.
SET THE TRAJECTORY